for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Glenmark Pharmaceuticals Ltd

GLEN.NS

Latest Trade

299.85INR

Change

11.30(+3.92%)

Volume

1,927,084

Today's Range

287.10

 - 

301.50

52 Week Range

270.00

 - 

705.90

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Latest Developments

Glenmark Pharmaceuticals Gets ANDA Approval For Abiraterone Acetate Tablets USP, 250 Mg

Oct 17 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::GLENMARK PHARMACEUTICALS LTD SAYS GETS ANDA APPROVAL FOR ABIRATERONE ACETATE TABLETS USP, 250 MG.

Glenmark Pharma Gets Tentative ANDA Approval For Dimethyl Fumarate Capsules

Oct 9 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::GETS TENTATIVE ANDA APPROVAL FOR DIMETHYL FUMARATE DELAYED‐RELEASE CAPSULES, 120 MG AND 240 MG.

Glenmark Pharmaceuticals Gets Nod For Combination Of Remogliflozin Etabonate And Metformin Hydrochloride

Aug 19 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::GETS NOD FOR COMBINATION OF REMOGLIFLOZIN ETABONATE AND METFORMIN HYDROCHLORIDE FOR ADULTS WITH TYPE 2 DIABETES IN INDIA.

India's Glenmark Pharmaceuticals June Qtr Consol Net Profit Falls

Aug 13 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::JUNE QUARTER CONSOL NET PROFIT 1.09 BILLION RUPEES VERSUS PROFIT OF 2.33 BILLION RUPEES LAST YEAR.<<<GLEN.NS>>> CONSENSUS FORECAST FOR JUNE QUARTER CONSOL PROFIT WAS 1.82 BILLION RUPEES.JUNE QUARTER CONSOL NET SALES 22.84 BILLION RUPEES VERSUS 21.29 BILLION RUPEES LAST YEAR.OVERALL PERFORMANCE IMPACTED DUE TO MODERATE PERFORMANCE IN U.S. AND SUBDUED PERFORMANCE IN LATAM.

Glenmark Pharmaceuticals Gets ANDA Approval For Ranolazine Extended-Release Tablets

July 9 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::GETS ANDA APPROVAL FOR RANOLAZINE EXTENDED-RELEASE TABLETS, 500 MG AND 1,000 MG.

Glenmark Pharmaceuticals To Partner With Novartis In Brazil

June 24 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::GLENMARK TO PARTNER WITH NOVARTIS TO PROMOTE, COMMERCIALIZE AND DISTRIBUTE THREE RESPIRATORY PRODUCTS IN BRAZIL.NOVARTIS WILL BE RESPONSIBLE TO MANUFACTURE PRODUCTS AND GLENMARK WILL EXCLUSIVELY COMMERCIALIZE THE PRODUCTS IN BRAZIL.DEAL BETWEEN UNITS GLENMARK FARMACÊUTICA & NOVARTIS BIOSCIENCES FOR 3 RESPIRATORY PRODUCTS.

Glenmark Pharmaceuticals Ltd Gets ANDA Approval For Solifenacin Succinate Tablets

May 21 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::RECEIVES ANDA APPROVAL FOR SOLIFENACIN SUCCINATE TABLETS, 5 MG AND 10 MG.

India's Glenmark Pharmaceuticals Gets ANDA Approval For Esomeprazole Magnesium Delayed-Release Capsules

May 14 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::GETS ANDA APPROVAL FOR ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 MG AND 40 MG.

Glenmark Pharmaceuticals Ltd Says Its Experimental Rhinitis Treatment Met Main Goal In Phase 3 Study

May 8 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::GLENMARK PHARMACEUTICALS LTD - K PHARMACEUTICALS ANNOUNCES RESULTS FROM A PHASE 3 STUDY OF RYALTRIS™, AN INVESTIGATIONAL PRODUCT FOR TREATMENT OF SEASONAL ALLERGIC RHINITIS, IN PATIENTS AGED 6 TO UNDER 12 YEARS.GLENMARK PHARMACEUTICALS - STUDY OF RYALTRIS IN PEDIATRIC PATIENTS AGED 6 TO UNDER 12 YEARS OF AGE MET ITS PRIMARY ENDPOINT.GLENMARK PHARMACEUTICALS- RESULTS FROM PHASE 3 STUDY OF RYALTRIS CONSISTENT WITH EXTENSIVE CLINICAL TRIAL EXPERIENCE WITH RYALTRIS IN PATIENTS 12 YRS OF AGE, OLDER.GLENMARK PHARMACEUTICALS LTD - IF APPROVED BY FDA, RYALTRIS WILL BE COMMERCIALIZED BY GLENMARK THERAPEUTICS INC USA.

Glenmark Pharmaceuticals Launches Anti‐Diabetes Drug Remogliflozin In India

April 30 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::SAYS LAUNCHES ANTI‐DIABETES DRUG REMOGLIFLOZIN IN INDIA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up